1. Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis). Issue 8 (8th June 2022) Authors: Malagoli, Piergiorgio; Dapavo, Paolo; Pavia, Giulia; Amoruso, Fabrizio; Argenziano, Giuseppe; Bardazzi, Federico; Burlando, Martina; Carrera, Carlo G.; Damiani, Giovanni; Dini, Valentina; Girolomoni, Giampiero; Guarneri, Claudio; Loconsole, Francesco; Narcisi, Alessandra; Sampogna, Francesca; Tra... Journal: Dermatologic therapy Issue: Volume 35:Issue 8(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis). (5th October 2022) Authors: Narcisi, Alessandra; Valenti, Mario; Gargiulo, Luigi; Ibba, Luciano; Amoruso, Fabrizio; Argenziano, Giuseppe; Bardazzi, Federico; Burlando, Martina; Carrera, Carlo Giovanni; Damiani, Giovanni; Dapavo, Paolo; Dini, Valentina; Franchi, Chiara; Girolomoni, Giampiero; Guarneri, Claudio; Loconsole, Fr... Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 37:Number 1(2023) Page Start: 93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗